SCHEMBL16427211

SCHEMBL16427211

CCOC(=O)c1c(Cl)cnn1CC(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4D Q08499 1/20 0.50
▸ PDE4B Q07343 1/20 0.48
▸ POLB P06746 3/20 0.47
▸ MAPT P10636 5/20 0.47
▸ TSHR P16473 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ LMNA P02545 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ SIRT3 Q9NTG7 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ S1PR4 O95977 1/20 0.44
▸ S1PR1 P21453 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ PAX8 Q06710 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16427380 0.91 PDE4D (0.52) PDE4DPDE4BPOLBMAPTTSHR
SCHEMBL16426583 0.89 PDE4B (0.50) PDE4BPOLBMAPTTSHRALDH1A1
SCHEMBL16426964 0.87 PDE4B (0.48) PDE4BPOLBMAPTTSHRALDH1A1
SCHEMBL16437441 0.85 PDE4D (0.55) PDE4DPDE4BPOLBMAPTTSHR
SCHEMBL16427745 0.82 PDE4B (0.50) PDE4DPDE4BPOLBMAPTTSHR
SCHEMBL16427759 0.77 PDE4B (0.50) PDE4BPOLBMAPTTSHRALDH1A1
SCHEMBL16437438 0.77 PDE4B (0.52) PDE4DPDE4BPOLBMAPTTSHR
SCHEMBL28058790 0.76 PDE4B (0.48) PDE4DPDE4BPOLBMAPTTSHR
SCHEMBL16437437 0.74 PDE4B (0.51) PDE4DPDE4BPOLBMAPTTSHR
SCHEMBL23112466 0.74 PDE4B (0.41) PDE4DPDE4BPOLBALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10005774-B2 Syk inhibitors GILEAD SCIENCES, INC. (US) 2018-06-26 — — US disclosed
EP-3027601-B1 SYK INHIBITORS GILEAD SCIENCES INC (US) 2017-10-25 — — EP disclosed
US-20160368918-A1 SYK INHIBITORS Kronos Bio, Inc. 2016-12-22 — — US disclosed
US-9376441-B2 Substituted pyrrolidines as SYK inhibitors GILEAD SCIENCES, INC. (US) 2016-06-28 — — US disclosed
EP-3027601-A1 SYK INHIBITORS Gilead Sciences, Inc. (US) 2016-06-08 — — EP disclosed
WO-2015017610-A1 SYK INHIBITORS GILEAD SCIENCES, INC. (US) 2015-02-05 — — WO disclosed
US-20150038488-A1 SYK INHIBITORS Kronos Bio, Inc. 2015-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038488-A1 SYK INHIBITORS SYK, BTK, LYN PDE4D 1210/4885PDE4B 1658/4885POLB 3881/4885
US-20160368918-A1 SYK INHIBITORS SYK, BTK, LYN PDE4D 1290/4885PDE4B 1728/4885POLB 3783/4885
US-10005774-B2 Syk inhibitors SYK, BTK, LYN PDE4D 1290/4885PDE4B 1728/4885POLB 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback